Group for Innovative Cancer TreatmentDivision of Supportive Care Research
In the Division of Supportive Care Research Laboratory, we are trying to develop novel compounds for 1) analgesics for intolerable and morphine-resistant severe pain, and 2) reduction of negative side effects of chemotherapy and symptoms of cancer cachexia. Further, translational research from innovative seeds to first-in-human exploratory clinical trials is our main area of focus in the laboratory. Development of such drugs by drug repositioning is also conducted for the improvement of quality of life in cancer patients.
Project Research Assistant
- First-in-human, second and third clinical trials to develop a novel analgesic for oral mucositis in cancer patients
- Development of novel compounds for the inhibition of platelet-activating factor (PAF) signaling loops, the pathway causing progression of severe chronic pain
- Development of novel and specific agonists for m/g opioid hetero-dimerized receptors
- Development of compounds for the improvement of cancer cachexic symptoms: clinical application of ghrelin and des-acyl ghrelin for the inhibition of cardiac intoxication from chemotherapy and/or improvement of symptoms of cancer cachexia
See also Research Projects.
See also Publications.
Division of Supportive Care Research, Exploratory Oncology Research & Clinical Trial Center
(Division of Cancer Pathophysiology, Research Institute)
Telephone: 03-3542-2511 (Ext: 3877)